Browsing tag:

type 2 Diabetes


An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]

Read More

As a treatment for Type 2 diabetes lixisenatide is approved by the EU and currently under review as a New Drug Application {NDA} by the FDA. Sanofi is preparing to launch lixisenatide in the European Union as in the latter of first quarter 2013, with the proprietary name Lyxumia. What makes lixisenatide unique is not[…]

Read More

Alogliptin is a current newsmaker in the pharmaceutical industry. On January 25, 2013 Takeda announced that Alogliptin, CAS# 850649-62-6, was approved alongside Metformin HCl, CAS# 1115-70-4, in the novel type 2 diabetes medication Kazano. As an efficacious and highly selective DPP-4 inhibitor, Alogliptin, when combined in this single dose tablet with metformin HCI effectively aids[…]

Read More

Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type[…]

Read More

As a chronic disease which occurs when the body does not properly produce, or use the hormone insulin, type 2 diabetes has become a worldwide problem. Roughly 25.8 million Americans and an estimated 366 million people worldwide have diabetes, according to the CDC and 2011 data from the IDF. Type 2 diabetes accounts for 90-95[…]

Read More

Glipizide, CAS number 29094-61-9, is also known as Glucotrol XL, which is marketed by Pfizer. With the patent due to expire in January of 2014, glipizide is set up for success as a generic alternative treatment for patients with type 2 diabetes. As an oral blood-glucose-lowering drug of the sulfonylurea class, glipizide is offered in[…]

Read More

Dapagliflozin, CAS number 461432-26-8, is currently being reviewed by the FDA for treatment of type 2 diabetes in adults. Developed by Bristol-Myers Squibb and AstraZeneca, the method of action of dapagliflozin is to inhibit the subtype 2 of the sodium-glucose transport proteins, or SGLT2. This particular subtype is responsible for at least 90% of the[…]

Read More

Liraglutide Diabetes Control Liraglutide is a newly developed drug that is used to control the levels of blood glucose in patients suffering from type 2 Diabetes. In January 2010, the US Food and Drug Administration approved this drug for the treatment of patients with diabetes. Liraglutide was approved by the European Medicines Agency (EMEA) in[…]

Read More

Metformin Hydrochloride is one of the most recommended medicines for the treatment of patients suffering from biguanide or type 2 Diabetes. According to recent studies, Metformin Hydrochloride reduces the LDL and triglyceride levels in the blood and hence it is one of the best medicines for diabetic patients who are also suffering with obesity. Studies[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service